CareDx Inc (CDNA)
23.42
-1.28 (-5.18%)
At close: Feb 20, 2025, 3:59 PM
23.38
-0.17%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 22.9 |
| Market Cap | 1.26B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.69 |
| PE Ratio (ttm) | -8.71 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 23.5 |
| Volume | 709,513 |
| Avg. Volume (20D) | 811,772 |
| Open | 24.44 |
| Previous Close | 24.70 |
| Day's Range | 22.70 - 24.51 |
| 52-Week Range | 7.42 - 34.84 |
| Beta | undefined |
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The co...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jul 17, 2014
Employees 635
Stock Exchange NASDAQ
Ticker Symbol CDNA
Website https://www.caredx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CDNA stock is "Hold." The 12-month stock price forecast is $29, which is an increase of 23.83% from the latest price.
Buy 57.14%
Hold 42.86%
Sell 0.00%
Next Earnings Release
CareDx Inc is scheduled to release its earnings on Feb 26, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+11.16%
CareDx shares are trading higher after Chevy Chase...
Unlock content with
Pro Subscription
4 months ago
-15.84%
CareDx shares are trading lower. The company reported preliminary Q3 financial results.
